Human iPSC Line (Episomal, CB)
|Catalog#||Unit||Unit Price (USD)||Actions|
|iPS18||>5x105 cells/vial||$1,557.68||Add to Cart|
Footprint-free human iPS18 cell lines generated by episomal plasmids are ideally suited for various research purpose including 1) differentiating various somatic cells or organoid models for phenotypic and target-based compound screening, 2) establishing genetically modified disease model through CRISPR/Cas9 editing, and 3) generating functional cells/tissues as regenerative biology initiatives. iPS18 has several features such as:
- Off the shelf - simple thaw the cells and plate them onto serum-free, feeder-free culture
- Transgene- and Virus-free (episomal)
- Homogeneity– Originated from a single iPSC clone
Footprint-free human iPS (induced pluripotent stem) cell line was derived from human new born cord blood (CB) mononuclear cells by ectopic expression of OCT4, SOX2, KLF4, L-MYC and Lin28 genes using episomal plasmids. The cells were derived using morphological selection criteria and without the use of fluorescent marker or drug selection. When cultured under standard human ES cell culture conditions, the morphology of human iPS cells are identical to that of human ES cells. The cells also express the pluripotency markers TRA-1-60, SSEA-3 and Oct4, and demonstrate strong endogenous alkaline phosphatase activity. High viability, low passage iPS cells have been pre-adapted to serum-free, feeder-free culture conditions.
|Product Name||Human iPSC Line (Episomal, CB)|
Dry Ice - Overnight Shipping
|Storage and Stability||
Store in vapor phase of liquid nitrogen immediately upon receipt. This product is stable for 12 months when stored as directed.
Human iPS cells were grown in feeder free conditions with mTeSR1 medium. Each lot of human iPS cells is tested for growth and viability following recovery from cryopreservation. In addition, each lot is tested for expression of TRA-1-60 and Oct4, as well as the activity of alkaline phosphatase.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures Cell Research (2011) 21:518-529.